Frequency of laboratory measurement and hyperkalaemia in hospitalised patients using serum potassium concentration increasing drugs

• DOI: 10.1007/s00228-011-1028-1
• Publication Date: 2011-03-18T10:11:10Z
• Authors: Esther V. Uijtendaal; Jeannette E. F. Z...; Wouter W. van Sol...; Toine C. G. Egberts
• Keywords: Adult; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Epidemiology; Pharmacoepidemiology and Prescription; Biomedische technologie en medicijnen; Farmacie/Biofarmaceutische wetenschappen (FARM); Cohort Studies; 03 medical and health sciences; 0302 clinical medicine; SDG 3 - Good Health and Well-being; Risk Factors; Humans; Pharmacology (medical); Drug Interactions; Netherlands; Ziekenhuisstructuur en organisatie van de gezondheidszorg; Pharmacology; Risk Management; Farmacie(FARM); 3. Good health; Hospitalization; Potassium; Hyperkalemia; Public Health; Drug Monitoring; Blood Chemical Analysis

Although, drug-drug interactions (DDIs) between potassium-increasing drugs (PIDs) are known risk factors for developing hyperkalaemia, not much is about their and management strategies during hospitalisation. This study examines the frequency of serum potassium measurements hyperkalaemia in hospitalised patients, based on use one or more PIDs, determinants thereof.Adult patients University Medical Centre Utrecht 2006 2008 were included this cross-sectional study. The compared using only PID at a time (monotherapy group) two PIDs concomitantly (interaction group). studied renal failure, diabetes mellitus, diuretics, type DDI, start within hospital versus continued home medication medical speciality.Serum was measured frequently interaction group than monotherapy [67 vs. 56%; relative (RR) 1.19, 95% confidence interval (CI) 1.14-1.24] also increased (9.9 5.9%, RR 1.7, CI 1.3-2.1). combination potassium-sparing diuretics plus supplement, hospitalisation non-internal medicine departments associated with higher estimates hyperkalaemia.Among our patient cohort, even when physicians received direct pop-up to monitor levels prescribing concomitantly, 33% 10% developed hyperkalaemia. Improved and/or clinical decision-support systems needed decrease following DDIs.